Novel Oral Agent Lowers HbA1c, Improves Beta-Cell Function in T2D

For the millions of patients with type 2 diabetes (T2D), lowering hemoglobin A1c (HbA1c) levels and maintaining the function of the pancreatic beta-cells are two therapeutic goals. New clinical data from ongoing trials with a oral glucose lowering agent provide insight into its value to T2D patients seeking to control their average levels of blood glucose and to maintain beta-cell function both initially and long term.

Breakthrough Data from COVALENT-111

Updated 52-week data from the Phase II study COVALENT-111 demonstrated that the benefits to glycemic parameters of insulin resistance induced by dexamethasone seen with 8-12 weeks of icovamenib treatment persisted for up to nine months after completion of treatment.

Why It Matters

The management of type 2 diabetes is focused on achieving adequate glucose lowering with consideration given to potential side effects and the ease of use of the prescribed medication. Glycemic control over a period of time is monitored by measuring HbA1c (glycated haemoglobin), which has a half-life of roughly the lifespan of the red blood cell, approximately 3 months. A large number of diabetes medications have been introduced to lower HbA1c, and most of these agents act by increasing insulin action, increasing insulin secretion, or decreasing absorption of intestinal glucose. An oral agent that can reduce HbA1c and improve beta-cell function, which is the underlying cause of hyperglycemia in type 2 diabetes, would address two important problems in the treatment of diabetes.

Beta Cells in the Pancreas

Restoring beta-cell function is a major therapeutic objective for diabetes since the pancreatic beta-cell is the insulin producing cell that fails in Type 2 Diabetes. While most patients with T2D ultimately experience a decline in beta-cell function requiring a change from oral medications to insulin injections, a therapeutic agent that could preserve or enhance beta-cell function could prevent some of this decline and delay progression to more intensive therapy. The long-term benefits to patients with hyperglycemia of such a therapeutic effect could be substantial.

The Role of Menin Inhibition

Icovamenib is a covalent menin inhibitor. Menin is an endogenous suppressor of pancreatic beta-cell regeneration. Inhibition of menin by icovamenib can promote pancreatic beta-cell regeneration.

1. Proliferate healthy, functional insulin-producing cells.
2. Preserve existing beta-cell mass from metabolic or autoimmune decay.
3. Reactivate dormant cells to restore endogenous insulin secretion.

Our data provide a possible explanation for the phenomenon, observed clinically for decades, whereby non-chronic interventions are capable of “resetting” the metabolic trajectory for several months to years.

Oral Options

From a system perspective, the emergence of an effective oral option for TNF will necessarily illuminate issues of access, care delivery and cost for a variety of stakeholders. From the perspective of the patient, the payer, and the health system, an oral TNF inhibitor is easier to take than an injectable TNF inhibitor, less costly for patients due to less training required to administer the medication, less stigma associated with taking the medication, and typically less expensive for patients. Decisions regarding acquisition cost versus savings from fewer complications, fewer clinic visits teaching a patient to administer injections, and fewer specialist visits will guide formulary decisions, coverage policies and out-of-pocket cost to the patient.

What the Research Shows

Impact on Severe Insulin-Deficient Diabetes (SIDD)

The most vulnerable patients in this study were those with severe insulin-deficient diabetes (SIDD). These patients, who have the lowest beta-cell function of all diabetes subtypes, are also the ones at highest risk of rapidly developing diabetes complications like diabetic retinopathy.

• HbA1c Reduction: In this difficult-to-treat group, a 12-week regimen of 100mg QD (Arm B) resulted in a 1.5% mean reduction in HbA1c at Week 52.
• Placebo-Adjusted Results: When compared to placebo, the reduction was even more pronounced at 1.8%.
• Disease Modification: These sustained reductions suggest a restoration of beta-cell function, addressing the root cause of the disease rather than just managing symptoms.

Synergy with GLP-1 Therapies

Results from the long-term follow-up in the open-label extension trial also supported an effective interaction between icovamenib and GLP-1-based therapies.

• Target Population: The study looked at patients who were already on a GLP-1 therapy but were failing to achieve their glycemic targets.
• Combined Efficacy: In this subgroup, a short course of icovamenib led to a 1.8% placebo-adjusted mean reduction in HbA1c at Week 52.
• Renewed Impact: This suggests that icovamenib may “give renewed impact” to GLP-1 agents, potentially by reviving the beta-cell mass required for those drugs to function optimally.

Who It Affects

Patients

The main group of patients for whom this treatment is of most benefit would be those with early or established type 2 diabetes. This particularly includes patients who have recently been diagnosed with high levels of residual beta-cell function, where effective glycaemic control can be achieved with oral medication whilst preserving endogenous insulin secretion. These patients may find an oral alternative a lifeline should they express aversion to injections, lack support at home or have difficulties with training. In these situations, improving adherence and patient outcome is likely to become easier.

Clinicians

Providers in primary care and endocrinology will consider where this new agent fits within their current treatment algorithm. Primary care physicians administer the majority of diabetes care and would initiate and monitor on daily basis this new oral therapeutic option, assuming it receives FDA approval and appropriate reimbursement. Endocrinologists would use this new option for the more complicated patients and to defer the need for intensive therapies in those patients who are rapidly deteriorating glycemic control and undergoing beta-cell deterioration.

Payers and Policymakers

In addition to considering the implications of such findings for patients and their treating physicians, it is also important to consider the potential effects on payers and policymakers. The goal of the research will be to help insurers understand whether or not the transient effects of an agent have any lasting offsets to costs. Policymakers and guideline bodies will use the information to develop treatment guidelines with respect to the relative effectiveness of different sequences of therapies potentially indicated for the same condition, as well as information relevant to developing inclusion or exclusion criteria for particular patient populations. From the perspective of the systems involved in pharmacy and pharmaceutical distribution, the focus will be on ensuring adequate supplies of effective therapies and fair distribution to urban and rural patients in need of such treatments.

What Changes

• Clinicians may have a new oral option that both lowers HbA1c and supports beta‑cell health, shifting treatment discussions earlier toward disease‑modifying approaches rather than solely symptom control.
• Primary care workflows could evolve to include initiation and follow‑up of this agent, reducing some referrals to specialty care while increasing the need for targeted monitoring and patient education.
• Coverage and affordability will be decisive. Payers will determine how accessible the drug is through formulary placement, prior authorization, or step therapy; these decisions will shape real‑world uptake and equity of access.
• Patient experience could improve for many through the avoidance of injections and simpler daily regimens, but attention to side effects, drug interactions, and expectations will remain essential to safe use.

Future Clinical Milestones

The preclinical data generated by Biomea Fusion within our emerging enzyme based biomanufacturing program is encouraging and positions us on an aggressive development path towards an IND filing in late 2025 and first in human studies in early 2026.

• COVALENT-211: A Phase IIb trial specifically for severe insulin-deficient T2D patients, expected to start in Q4 2025.
• COVALENT-212: A Phase II trial evaluating the combination of icovamenib and GLP-1 therapies, also slated for Q4 2025.
• COVALENT-121: An ongoing food-effect study to optimize dosing, expected to conclude by December 2025.
• BMF-650 (GLP-131): Initiation of a Phase I trial for Biomea’s own oral GLP-1 receptor agonist in obese volunteers is ongoing, with data expected in the first half of 2026.

Why clinicians should care

From a clinical perspective, key questions are: Which patients would benefit from this additional option to diabetes therapy? How and when should clinicians monitor effects of this medication (e.g., improvement in beta-cell function), and what are the absolute benefits and harms of this agent in relation to alternative treatments for diabetes. The agent may be particularly useful in patients with recent onset of T2D (or even new onset and obesity) or unpredictable fasting or postprandial glucose levels, either consistent or intermittent over time, despite optimal lifestyle and therapy with other oral diabetes medications. Shared decision making with patients is critical in discussing the magnitude and durability of HbA1c reduction and the probability that additional therapy will be required. Clinicians must also weigh the benefits of this new option with its side effects and increased cost.

Apart from looking out for any additional problems that may emerge early on, patient monitoring will be essentially unchanged. We will monitor for signs of intolerance as well as the potential for hypoglycemia, especially when combining the new agent with medications known to increase the risk of hypoglycemia (e.g. insulin, oral sulfonylureas). Dosage adjustments will take into account the patient’s renal and hepatic function as well as potentially interactive medications (e.g. warfarin).

Patient experience and practical care considerations

From the patient’s point of view, most would prefer an oral preparation to a parenteral one because, in general, equivalent therapeutic effect can be achieved with a single or twice daily oral preparation as opposed to a daily or more frequent injection. Many oral drugs for diabetes reduce the “medical” aspect of diabetes management by reducing or eliminating the need for insulin or other injectable therapies between meals or at bedtime. However, there are a number of potential barriers to adherence with oral diabetes medications. To maximize adherence, patients and their providers must be well informed of the benefits and risks of diabetes therapy, as well as the steps to be taken in the event of side effects.

Behavioral support of pharmacotherapy is critical and all of the lifestyle interventions that we have been taught such as healthy eating, physical activity, smoking cessation and weight management need to continue to be a central part of our treatment plan. This new oral medication is one of the pieces of our treatment plan that can offer glycemic control and the long-term effects on risk factors such as heart disease. Patients and their health care providers as well as diabetes educators, pharmacists and community health workers will be crucial for initiating and continuing this treatment.

System-level implications and policy trade-offs

Initial formulary and prior authorization positioning (i.e., within formulary categories and prior authorization indications) will restrict adoption. The initial price point is high, and payers will limit use to very selective patient populations. Companies will require cost-effectiveness analyses and real-world evidence to demonstrate additional benefits to payers. These benefits may include delayed initiation of insulin therapy, reduced risk of diabetes-related complications, and fewer or less complex specialty visits.

The need to address issues related to the work-force and training of the healthcare work-force and to develop decision support tools for practitioners, including those in primary care settings where these drugs first will be encountered by health care providers (e.g., physicians, nurses, pharmacists), as well as by patients themselves, will be a consideration. In addition to materials that can guide health care providers in the initiation and follow-up of therapy with these drugs, the package insert and materials distributed by pharmacists in retail settings need to include clear information about side effects and drug interactions. Every effort should be made to ensure that these materials are distributed equitably to rural and disadvantaged populations to ensure that they are not left behind.

Risks, trade‑offs, and unanswered questions

No treatment is perfect. Most of the current therapies for type 2 diabetes have side effects, such as gastrointestinal problems or changes in metabolism, and some have the potential to interact with other medications. Although the risk for causing hypoglycemia with most current oral diabetes medications is less than that for insulin or some older diabetes medications, the risk increases when several agents are given in combination. Clinicians are awaiting more information about the long-term safety and durability of therapies that improve beta-cell function.

While there are certainly advantages of new therapies for diabetes and its complications, there are also trade-offs between the novel information obtained about efficacy and/or safety from clinical trials and the more established information gained from experience with currently marketed products, including data on duration of use. Novel therapies enter the system with a brief history of effect on cardiovascular and renal outcomes, important to payers and guidelines. Post‑market surveillance and the development of registries will be necessary to obtain longer-term experience with these new therapies and to identify rare adverse events as they occur.

Looking ahead

If supportive data on durable effects on HbA1c and beta-cell function together with supportive data on safety and tolerability on a long-term horizon are available, the drug might be recommended for the use in treatment escalation, in particular in early onset patients. However, real-world studies, cost-effectiveness analyses etc. will help to show in which patients the biggest value is added compared to other current treatment options.

Preparation of the system and providers will also be critical including education of clinicians, coverage decisions, and monitoring of both benefits and harms for these new medications in various populations. These new medications will potentially offer patients an easy to take daily oral medication to control blood sugar and support the pancreas, which may delay the need for more intensive management options.

The potential of this new oral diabetes treatment to improve glycemic control and beta-cell protection must be weighed against the potential risks, costs, and limitations of this treatment and how it will impact the prevention of diabetes-related complications over time. The ultimate decision to incorporate this new treatment option into clinical practice will depend upon the potential benefits weighed against the potential trade-offs to safe and effective use.